company background image
UMED

Unité de Fabrication des MédicamentsBVMT:UMED Stock Report

Market Cap

د.ت237.8m

7D

-4.3%

1Y

-31.3%

Updated

26 Oct, 2021

Data

Company Financials
UMED fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends0/6

UMED Overview

Unité de Fabrication des Médicaments S.A.

Price History & Performance

Summary of all time highs, changes and price drops for Unité de Fabrication des Médicaments
Historical stock prices
Current Share Priceد.ت7.27
52 Week Highد.ت6.69
52 Week Lowد.ت10.95
Beta0.092
1 Month Change6.91%
3 Month Change2.39%
1 Year Change-31.29%
3 Year Change-13.45%
5 Year Change-22.25%
Change since IPO-30.17%

Recent News & Updates

Shareholder Returns

UMEDTN PharmaceuticalsTN Market
7D-4.3%1.7%-1.8%
1Y-31.3%89.9%-1.1%

Return vs Industry: UMED underperformed the TN Pharmaceuticals industry which returned 89.9% over the past year.

Return vs Market: UMED underperformed the TN Market which returned -1.1% over the past year.

Price Volatility

Is UMED's price volatile compared to industry and market?
UMED volatility
UMED Beta0.092
Industry Beta0.56
Market Beta1

Stable Share Price: UMED is not significantly more volatile than the rest of TN stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: UMED's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989n/aRidha Charfeddinehttps://www.unimed.com.tn

Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company’s products include ophta-ORL solutions, liquids for injections, penicillin powders, cephalosporins for injections, inhalations, and perfusion solutions, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It also manufactures medicines for third party laboratories.

Unité de Fabrication des Médicaments Fundamentals Summary

How do Unité de Fabrication des Médicaments's earnings and revenue compare to its market cap?
UMED fundamental statistics
Market Capد.ت237.76m
Earnings (TTM)د.ت6.26m
Revenue (TTM)د.ت86.06m

37.1x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UMED income statement (TTM)
Revenueد.ت86.06m
Cost of Revenueد.ت40.90m
Gross Profitد.ت45.15m
Expensesد.ت38.89m
Earningsد.ت6.26m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.20
Gross Margin52.47%
Net Profit Margin7.28%
Debt/Equity Ratio32.8%

How did UMED perform over the long term?

See historical performance and comparison

Valuation

Is Unité de Fabrication des Médicaments undervalued compared to its fair value and its price relative to the market?

32.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: UMED (TND7.3) is trading below our estimate of fair value (TND10.71)

Significantly Below Fair Value: UMED is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: UMED is poor value based on its PE Ratio (37.3x) compared to the African Pharmaceuticals industry average (9.5x).

PE vs Market: UMED is poor value based on its PE Ratio (37.3x) compared to the TN market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UMED's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UMED is overvalued based on its PB Ratio (2.2x) compared to the XF Pharmaceuticals industry average (1.5x).


Future Growth

How is Unité de Fabrication des Médicaments forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Unité de Fabrication des Médicaments has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Unité de Fabrication des Médicaments performed over the past 5 years?

-2.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UMED has high quality earnings.

Growing Profit Margin: UMED's current net profit margins (7.3%) are lower than last year (13%).


Past Earnings Growth Analysis

Earnings Trend: UMED's earnings have declined by 2.7% per year over the past 5 years.

Accelerating Growth: UMED's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: UMED had negative earnings growth (-49.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).


Return on Equity

High ROE: UMED's Return on Equity (6%) is considered low.


Financial Health

How is Unité de Fabrication des Médicaments's financial position?


Financial Position Analysis

Short Term Liabilities: UMED's short term assets (TND73.4M) exceed its short term liabilities (TND19.9M).

Long Term Liabilities: UMED's short term assets (TND73.4M) exceed its long term liabilities (TND26.1M).


Debt to Equity History and Analysis

Debt Level: UMED's debt to equity ratio (32.8%) is considered satisfactory.

Reducing Debt: UMED's debt to equity ratio has increased from 5.2% to 32.8% over the past 5 years.

Debt Coverage: UMED's debt is well covered by operating cash flow (63.9%).

Interest Coverage: UMED's interest payments on its debt are well covered by EBIT (4.2x coverage).


Balance Sheet


Dividend

What is Unité de Fabrication des Médicaments's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate UMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UMED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UMED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UMED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: UMED is not paying a notable dividend for the TN market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UMED's dividend in 3 years as they are not forecast to pay a notable one for the TN market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Ridha Charfeddine

1.33yrs

Tenure

Mr. Ridha Charfeddine is the Chief Executive Officer at Unité de Fabrication des Médicaments since June 12, 2020. He is the President of the Board of Directors at Société UNIMED.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Unité de Fabrication des Médicaments's employee growth, exchange listings and data sources


Key Information

  • Name: Unité de Fabrication des Médicaments
  • Ticker: UMED
  • Exchange: BVMT
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: د.ت237.760m
  • Shares outstanding: 32.00m
  • Website: https://www.unimed.com.tn

Number of Employees


Location

  • Unité de Fabrication des Médicaments
  • Industrial Zone Kalaa Kebira, BP 38
  • Sousse
  • 4060
  • Tunisia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 16:24
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.